ProBioGen and Spica Therapeutics collaborate on MAb

9 December 2025

German contract development and manufacturing company ProBioGen and Spica Therapeutics, a pioneering Belgian biotech advancing pathogenic macrophage subset-targeted immunotherapies, today announced a new collaboration.

The deal will see ProBioGen perform cell line development for ST101, Spica’s first clinical development candidate anti-CD163 depleting antibody for oncology. ST101 is a first-in-class monoclonal antibody (MAb) designed to selectively deplete immunosuppressive CD163+ tumor-associated macrophages (TAMs). Spica has integrated ProBioGen’s proprietary GlymaX technology to boost antibody-dependent cell-mediated cytotoxicity (ADCC). No financial terms were disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK